The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis
Ann Rheum Dis. 2014 Nov 14. pii: annrheumdis-2014-206028. doi: 10.1136/annrheumdis-2014-206028. [Epub ahead of print]
Keywords:
Lipid profile changes in patients with chronic inflammatory arthritis treated with biologics and tofacitinib in randomized clinical trials: A systematic review and meta-analysis
Arthritis Rheumatol. 2015;67(1):117–127
The s...
Keywords:
An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy
Arthritis Rheumatol. 2015;67(2):372–380
Keywords:
Combined inhibition of TNFα and IL-17 as therapeutic opportunity for treatment in rheumatoid arthritis: Development and characterization of a novel bispecific antibody
Arthritis Rheumatol. 2015;67(1):51–62
October 2014
Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: Patient-reported outcomes from a Phase 3 trial
Arthritis Care Res (Hoboken). 2014 Sep 3. doi: 10.1002/acr.22453. [Epub ahead of print]
This paper presents patient-reported outcomes (PROs) form the ORAL Step trail, which assessed tofacitinib 5 mg or 10 mg twice daily, or ...
Keywords:
September 2014
The active metabolite of spleen tyrosine kinase inhibitor fostamatinib abrogates the CD4+T cell-priming capacity of dendritic cells
Rheumatology (Oxford). 2015;54(1):169–177
In these murine studies, investigators sought to gain an understanding of how the active metabolite of fostamatini...
Keywords:
Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
N Engl J Med. 2014;371(4):326–338.
These two pivotal phase 3 studies in plaque psoriasis, FIXTURE and ERAUSRE, were sponsored by Novartis Pharmaceuticals. Secukinumab met all primary endpoints, PASI 75 response and the response of 0 or 1 on the modified investigator’s global assessment, as well as key secondary end...
Keywords:
August 2014
Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials
Arthritis Res Ther. 2014;16(4):R158
Serum creatinine values and renal adverse event data were pooled from patients who received =1 dose of tofacitinib either with background DMARDs or as monotherapy in five Phase 3 studie...
Keywords:
Analysis of Infections and All-Cause Mortality in Phase II, III and Long-Term Extension Studies of Tofacitinib in Patients with Rheumatoid Arthritis
Arthritis Rheumatol. 2014;66(11):2924–2937
The overall incidence rate of serious infections was 3.09 events/100 patient-years (95% CI 2.73–3.49), which was stable over time, with pneumonia and skin and soft...
Keywords:
July 2014
Herpes Zoster and Tofacitinib Therapy in Patients with Rheumatoid Arthritis
Arthritis Rheumatol. 2014 Jun 18. [Epub ahead of print]